Last line therapy with sorafenib in colorectal cancer: A retrospective analysis

作     者：Ksenia Martchenko Irene Schmidtmann Thomas Thomaidis Verena Thole Peter R Galle Marc Becker Markus Mohler Thomas C Wehler Carl C Schimanski 

作者机构：Department of Internal Medicine Marienhospital 64285 Darmstadt Germany Institute of Medical Biostatistics Epidemiology and Informatics Johannes Gutenberg University Hospital of Mainz 55131 Mainz Germany First Department of Internal Medicine Johannes Gutenberg University Hospital of Mainz 55131 Mainz Germany Department of Internal Medicine Katholische Kliniken Mainz 55131 Mainz Germany Institute of Pathology Saarland University Medical Center 66421 Homburg Germany Third Department of Internal Medicine Johannes Gutenberg University Hospital of Mainz 55131 Mainz Germany 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2016年第22卷第23期

页      面：5400-5405页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Colorectal cancer Sorafenib Regorafenib Chemotherapy Last line 

摘      要：AIM: To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients. METHODS: All patients receiving chemotherapy for colorectal cancer in the outpatient clinic of the University of Mainz since 2006 were retrospectively analyzed for last line sorafenib exposure. Charts of identified patients were analyzed for clinic-pathological parameters, like data on gender, age, date of initial diagnosis, UICC stage, number and kind of the pretherapies, therapy start and end of sorafenib, sorafenib mediated treatment cessation, side effects, response rates, time to progression and overall survival. RESULTS: Ten patients with a median of 3.0 prior chemotherapy lines had received a last line sorafenib therapy either alone(10%) or in combination with 5-fluorouracil derivates(90%). All patients suffered from colorectal cancer stage UICC 4 and were routinely seen in 2-wk intervals in the oncology outpatient clinic. Median duration of treatment was 142.0 d. At 8 wk 80% of patients showed stable disease but we did not observe any remissions. Median time to progression was 140.5 d(4.7 mo), while median overall survival reached 176.5 d. One patient ceased treatment due to side effects. Reason for treatment stop was bleeding complication in one case and non-specified sorafenib intolerance in another case. Due to the retrospective approach we did not further quantify side ***: This retrospective analysis encourages further investigation of sorafenib in colorectal cancer last line therapy.